Description: Molecular Basis for Therapy of AIDS-Defining Cancers by Dirk P. Dittmer, Susan E. Krown Cancer incidences increase in people living with HIV/AIDS. This number will increase as HAART prolongs the average lifespan and as (at least in some states) the number of new HIV infections increase again. FORMAT Paperback LANGUAGE English CONDITION Brand New Publisher Description Cancer incidences increase in people living with HIV/AIDS. Over 2 million people currently live with HIV/AIDS in the US. This number will increase as HAART prolongs the average lifespan and as (at least in some states) the number of new HIV infections increase again. As this population ages their incidence rates for cancer will increase, as well.Recently, new rational targets for cancer therapy have emerged. But their application to the care of HIV+ patients is slow, because of concerns about the weakened immune status of the patients, because of possible drug interactions with HAART and because some of the AIDS defining cancer are rare. Back Cover An increased risk for various cancers is a characteristic of people living with HIV infection. Although only three cancers - Kaposis sarcoma, high-grade B-cell lymphomas, and invasive cervical cancer - are considered to be "AIDS-defining" conditions, are associated with oncogenic viruses, and occur with increased frequency as immune function declines, other cancer types also occur significantly more frequently in HIV-positive individuals than in the general population, but are not directly associated with clinical progression to AIDS. Notably these "non-AIDS-defining" cancers include virus-associated cancers such as anal cancer, hepatocellular cancer and Hodgkins disease, as well as non-virus associated cancers such as lung cancer. Importantly, there are also large worldwide differences in the incidence and behavior of different AIDS-associated cancers. Although effective combination antiretroviral therapy (cART) may be sufficient in some cases to decrease the incidence or beneficially influence the course of some cancers, in other cases it fails to control cancers in people living with HIV/AIDS. Currently, more than a decade after the widespread introduction of cART, and after major advances in the basic understanding of cancer signaling pathways, we have a unique opportunity to revisit the pathobiology, epidemiology and treatment options for malignancies in people living with HIV/AIDS. Molecular Basis for Therapy of AIDS-Defining Cancers provides a primer on the science of cancer in the setting of HIV infection, as well as examples of novel treatment approaches for HIV-associated neoplasia. Table of Contents The Epidemiology of Cancer in People with HIV.- Epidemiology and Clinical Characteristics of Non-AIDS-Defining Malignancies.- HIV-Related Cancer Management in Resource-Limited Settings: A Case Study of Malawi.- Immunology of HIV-Associated Kaposi Sarcoma.- Targeting Signal Transduction Pathways for the Treatment of Kaposi Sarcoma.- Role of NF-?B Inhibitors in HIV-Related Malignancies.- The Molecular Basis of Lytic Induction Therapy in Relation to Gamma herpesvirus (KSHV, EBV)-Associated, AIDS-Related Tumors.- Viral Interleukin-6: Molecular Biology and Pathogenesis.- Targeting the PI3K/Akt/mTOR Pathway in AIDS-Associated Malignancies.- Restoration of p53 Function by MDM2 Inhibition: Potential Strategy to Treat KSHV-Associated Malignancies.- Interferon in Kaposis Sarcoma Biology and Therapy.- Metronomic Therapy for HIV-Associated Malignancies.- Targeting EGFR in HPV-Associated Cancer.- Cidofovir Against Human Papillomavirus-Associated Diseases. Long Description Cancer incidences increase in people living with HIV/AIDS. Over 2 million people currently live with HIV/AIDS in the US. This number will increase as HAART prolongs the average lifespan and as (at least in some states) the number of new HIV infections increase again. As this population ages their incidence rates for cancer will increase, as well. Recently, new rational targets for cancer therapy have emerged. But their application to the care of HIV+ patients is slow, because of concerns about the weakened immune status of the patients, because of possible drug interactions with HAART and because some of the AIDS defining cancer are rare. Feature Will provide an update of the latest treatments for AIDS defining cancers, a scientific rationale for established treatments and a review of novel molecularly-targeted treatment options, which have passed pre-clinical testing Details ISBN1489982000 Year 2014 ISBN-10 1489982000 ISBN-13 9781489982001 Publication Date 2014-09-06 Format Paperback Short Title MOLECULAR BASIS FOR THERAPY OF Language English Media Book Imprint Springer-Verlag New York Inc. Place of Publication New York Country of Publication United States Edited by Susan E. Krown Edition 2010th Pages 256 AU Release Date 2014-09-06 NZ Release Date 2014-09-06 US Release Date 2014-09-06 UK Release Date 2014-09-06 Author Susan E. Krown Publisher Springer-Verlag New York Inc. Edition Description 2010 ed. Alternative 9781441915122 DEWEY 616.994 Audience Professional & Vocational Illustrations XIII, 256 p. We've got this At The Nile, if you're looking for it, we've got it. With fast shipping, low prices, friendly service and well over a million items - you're bound to find what you want, at a price you'll love! TheNile_Item_ID:96249357;
Price: 314.31 AUD
Location: Melbourne
End Time: 2025-01-04T21:06:53.000Z
Shipping Cost: 9.58 AUD
Product Images
Item Specifics
Restocking fee: No
Return shipping will be paid by: Buyer
Returns Accepted: Returns Accepted
Item must be returned within: 30 Days
ISBN-13: 9781489982001
Book Title: Molecular Basis for Therapy of AIDS-Defining Cancers
Number of Pages: 256 Pages
Language: English
Publication Name: Molecular Basis for Therapy of Aids-Defining Cancers
Publisher: Springer-Verlag New York Inc.
Publication Year: 2014
Subject: Medicine
Item Height: 235 mm
Item Weight: 421 g
Type: Textbook
Author: Susan E. Krown, Dirk P. Dittmer
Item Width: 155 mm
Format: Paperback